Achondroplasia management in the era of targeted therapies: a meta-analysis of C-type natriuretic peptide analogs.
CNP analogs like vosoritide show statistically significant but modest improvements in growth for children with achondroplasia, alongside some safety concerns regarding specific adverse events.
Where it sits
this study against the rest of the vosoritide corpusSummary and findings
This meta-analysis evaluated the safety and efficacy of C-type natriuretic peptide (CNP) analogs, specifically vosoritide, in children with achondroplasia. The study included 11 studies with a total of 542 participants, focusing on annualized growth velocity and adverse events. Findings indicated statistically significant increases in growth metrics but highlighted safety concerns regarding specific adverse events.
Abstract
<h4>Context</h4>No prior meta-analysis has systematically assessed efficacy and safety of C-type natriuretic peptide (CNP) analogs within the context of evolving understanding of FGFR3 biology and achondroplasia natural history.<h4>Objective</h4>To evaluate the safety and efficacy of CNP analogs in children with achondroplasia and contextualize clinical outcomes and natural history.<h4>Methods</h4>Systematic review of randomized control trials and real-world studies evaluating the safety and efficacy of CNP analogs (vosoritide and navepegritide) in children aged <18 years with genetically confirmed achondroplasia was performed. Coprimary outcomes of interest were adverse events (AEs) and changes from baseline in annualized growth velocity (AGV) at the end of the trials. Secondary outcomes included changes from baseline in height <i>Z</i>-score, standing height, and upper-to-lower body segment (ULS) ratio.<h4>Results</h4>Eleven studies (<i>N</i> = 542) were included, of which 4 RCTs (<i>n</i> = 326) with low overall risk of bias were meta-analyzed. Overall and serious AE rates were comparable between CNP analogs and placebo, except for higher relative risks of injection site reactions (1.65), urticaria (4.04), and swelling (3.57). C-type natriuretic peptide analogs significantly increased mean differences in AGV (1.36 cm/year; 95% CI: 1.05-1.68; <i>P</i> < .00001) and standing height (1.24 cm; 95% CI: 0.47-2.01; <i>P</i> = .002), without short-term effect on ULS ratio. Real-world studies demonstrated sustained growth benefits with infrequent serious AEs or treatment discontinuations.<h4>Conclusion</h4>C-type natriuretic peptide analogs provide slight but statistically meaningful improvements in linear growth in children with achondroplasia with acceptable short-term safety profile. Long-term studies are needed to define optimal timing of therapy on adult height, functional outcomes, and achondroplasia-related complications.
Background
This paper addresses the efficacy and safety of C-type natriuretic peptide (CNP) analogs in treating children with achondroplasia, a condition characterized by impaired growth due to mutations in the FGFR3 gene. Prior to this meta-analysis, there had been no systematic evaluation of CNP analogs in this context, despite their potential to influence growth outcomes. Understanding the effects of these therapies is crucial as they represent a targeted approach to managing a genetic disorder.
Methods
The study conducted a systematic review of randomized control trials and real-world studies involving children under 18 years with genetically confirmed achondroplasia. A total of 11 studies were included, with 4 RCTs comprising 326 participants being meta-analyzed. The primary outcomes were adverse events and changes in annualized growth velocity, while secondary outcomes included changes in height Z-score, standing height, and upper-to-lower body segment ratio.
Results
The primary endpoint showed a significant increase in annualized growth velocity of 1.36 cm/year (95% CI: 1.05-1.68, P < .00001) with CNP analogs compared to placebo. Additionally, standing height increased by 1.24 cm (95% CI: 0.47-2.01, P = .002). Adverse events were comparable between CNP analogs and placebo, but specific injection site reactions, urticaria, and swelling had higher relative risks.
Interpretation
The findings suggest that CNP analogs provide statistically significant improvements in growth metrics for children with achondroplasia, although the effect sizes may be considered small in a clinical context. The increased risks of certain adverse events, particularly urticaria and injection site reactions, warrant caution. The limitations of the study, including the reliance on a small number of trials and the short duration of follow-up, suggest that further research is necessary to fully understand the long-term safety and efficacy of these therapies.
Key findings
- 1.36 cm/year increase in annualized growth velocity, 95% CI: 1.05-1.68, P < .00001.
- 1.24 cm increase in standing height, 95% CI: 0.47-2.01, P = .002.
- Relative risk of injection site reactions was 1.65.
- Relative risk of urticaria was 4.04.
- Relative risk of swelling was 3.57.
Limitations
- small n=542 across 11 studies
- limited long-term safety data
- specific adverse events raised safety concerns
- short follow-up duration
- potential publication bias in included studies